Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma - PubMed
2 hours ago
- #CAR-T therapy
- #bridging therapy
- #multiple myeloma
- Bridging therapy (BT) prior to anti-BCMA CAR-T aims to reduce tumor burden and improve patient performance status without causing toxicity that delays CAR-T infusion.
- Expert consensus emphasizes tailoring BT selection to patient characteristics, especially for difficult-to-treat populations, balancing treatment duration and response adequacy.
- Talquetamab, a GPRC5DxCD3 bispecific antibody, shows strong efficacy and rapid response in trials and is considered a promising BT option before anti-BCMA CAR-T therapy.
- The consensus provides guidance to standardize care and assist healthcare professionals in using BT effectively to enhance outcomes of anti-BCMA CAR-T therapy.